Biogen, UCB release phase 3 data on lupus candidate dapirolizumab
Phase 3 trial of Biogen and UCB's dapirolizumab pegol shows significant improvement in lupus disease activity. Read more here ...
Biogen股价触及52周低点156.9美元，面临挑战
Biogen Idec Inc的股价已触及52周低点，交易价格为156.9美元，反映出这家生物技术公司正经历一段充满挑战的时期。过去一年，该公司股价下跌了31.68%，表明投资者存在重大担忧，市场压力较大。这一下滑发生在整个行业波动性较大的背景下，同时公司还面临着特定的障碍，包括竞争激烈的市场动态和产品管线的挫折。投资者正密切关注Biogen的战略举措，以重振增长并重获市场信心。 在其他近期新闻中 ...
Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now
We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...
Biogen cut to hold by Needham on lack of catalysts, slow Leqembi sales
Needham has downgraded Biogen (NASDAQ:BIIB) to hold from buy, citing a lack of near-term catalysts and slow uptake for the ...
Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
Needham downgraded Biogen Inc (NASDAQ:BIIB), citing limited catalysts for the company over the next year. Alzheimer’s drug ...
BioSpace21 小时
Biogen, UCB Reveal Details Behind Surprise Late-Stage Win in Lupus, Eyes Second Phase III
After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...
BioSpace40 分钟
RFK Jr.’s HHS Nomination, Biogen’s Lupus Win and Leqembi Struggles, Neurogene’s Rough ...
Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.
花旗以中性评级和190美元目标价开始对Biogen的覆盖
周三，花旗开始对Biogen (NASDAQ:BIIB)股票进行覆盖，给予中性评级，并设定190美元的目标价。这一新的覆盖反映了对这家生物技术公司财务前景的谨慎态度，主要是由于其传统业务面临压力。 Biogen的核心产品，包括用于多发性硬化症(MS)、脊髓性肌萎缩症(SMA)的治疗以及来自抗CD20疗法的特许权使用费，年复合增长率(CAGR)分别下降了12%、3%和2%。为了应对这些下降，公司致力 ...
Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug
Biogen’s stock rose 1% Thursday, after Europe’s pharmaceutical regulator issued a positive opinion on the Alzheimer’s disease ...
EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection
The European Union's drugs regulator on Thursday recommended approval of Eisai and Biogen's Leqembi for some patients with ...
European committee takes a second look at Alzheimer’s drug and now says it should be approved
A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease ...